Search the Community
Showing results for tags 'research'.
Found 14 results
-
LUNGevity Foundation, the nation’s leading lung cancer-focused organization, announced the funding of two research teams that will focus on lung cancer interception: catching precancerous cells and blocking them from turning into cancer cells. These awards are the first-ever Stand Up To Cancer awards focused on the early detection and interception of lung cancer and build on LUNGevity’s eight-year direct investment in critical early detection lung cancer research. "Finding lung cancer early, when it is most treatable, is a critical step to saving thousands of lives," said Andrea Ferris, President and CEO of LUNGevity, "especially since currently only 15% of patients are diagnosed at this stage. Our long-term strategic focus and investment in finding better ways to detect, diagnose, and now intercept lung cancer in its earliest stages is strengthened by this collaboration with SU2C and the American Lung Association’s LUNG FORCE initiative. It is our goal to find noninvasive, widely available diagnostic and early detection tools that will dramatically change outcomes for people with lung cancer.” The interdisciplinary and multi-institutional awards include a Lung Cancer Interception Dream Team, and a Lung Cancer Interception Translational Research Team. SU2C-LUNGevity Foundation-American Lung Association Lung Cancer Interception Dream Team: Intercept Lung Cancer Through Immune, Imaging, & Molecular Evaluation (InTIME) Funding: $5 million Leader: Avrum Spira, MD, professor of medicine, pathology and bioinformatics, and director of the Cancer Center at Boston University-Boston Medical Center Co-leader: Steven Dubinett, MD, associate vice chancellor for research at UCLA and director of the lung cancer research program at the Jonsson Comprehensive Cancer Center The Lung Cancer Interception Dream Team will develop diagnostic tools, such as nasal swabs, blood tests, and radiological imaging, to confirm whether lung abnormalities found on chest imaging are benign lung disease or lung cancer. To protect against recurrence of disease that has already been successfully treated, new blood tests will help identify patients at the earliest stages of recurrence, enabling timely interventions such as immunotherapy. "We plan to develop technology that can, in a very sensitive way, pick up the small amount of DNA that might be present in the blood of someone who’s harboring a lung cancer deep within their lung tissue – a noninvasive way of measuring a person’s risk of having lung cancer," Dr. Spira said. SU2C-LUNGevity Foundation-American Lung Association Lung Cancer Interception Translational Research Team: Blood-based Early Interception of Lung Cancer Funding: $2 million Leader: Lecia Sequist, MD, MPH, associate professor of medicine, and director of the Center for Innovation in Early Cancer Detection (CIECD) at Massachusetts General Hospital Co-leader: Maximilian Diehn, MD, PhD, assistant professor of radiation oncology, Stanford University School of Medicine The Lung Cancer Interception Translational Research Team will develop a lung cancer interception assay (LCIA) that can be used in conjunction with low-dose CT scans, based on blood-based assays that examine circulating tumor cells and circulating tumor DNA. After completing pilot testing as part of this Translational Research Grant, the team plans to move the LCIA forward to larger, prospective clinical trials. "It’s extremely frustrating that we’re not technically able to find lung cancer earlier in the majority of patients,” Dr. Sequist said. “We need to change the paradigm that we use to identify patients so that they are found early enough to offer them curative treatment. If we really want to save more lives from lung cancer, we have to exponentially improve our diagnostics." LUNGevity is the only lung cancer nonprofit with a programmatic focus on funding early detection research, to find lung cancer when it is most treatable. Currently, only 15% of people with lung cancer are diagnosed in the earliest stages, resulting in a 5-year survival rate of only 17.7%. These projects expand on LUNGevity’s eight-year investment in early detection research with the goal of developing an effective, widely available, noninvasive way of finding lung cancer early in all populations. Click here to read the full press release.
-
Find A Cure Panel specializes in patient research for rare and serious disease and they have some current research for people and caregivers of people with Small Cell Lung Cancer (SCLC). To qualify for this research, you or your loved one with Small Cell Lung Cancer (SCLC): 1) Must have a diagnosis with Small Cell Lung Cancer (SCLC). 2) Be over 50 years old. 3) Have EXTENSIVE SCLC. Sometimes referred to as stage 3, stage 4 or metastatic SCLC. 4) Must have some experience with smoking. If you/your loved one NEVER SMOKED then you won’t qualify, unfortunately. 5) If you are a caregiver, you must be knowledgeable about your loved one’s condition and treatment. 6) If you are a caregiver who recently lost your loved one with SCLC, you can still participate if you lost your loved one in the last 12 months. It is easy to participate in. It’s one confidential and anonymous phone call with one moderator talking about your experience with Small Cell Lung Cancer (SCLC). If you are interested in participating, please contact FACP at info@findacurepanel.com and reference FACP/SCLC
-
This organization is looking for people who are willing to share their opinions about Non-Small Cell Lung Cancer. They are looking to speak with patients (ages 18-80) and caregivers with Stage III or IV Non-Small Cell Lung Cancer. Qualified participants will be compensated $100 (Telephone Interview) OR $150 (Focus Group) for their time and opinion. Anyone who is interested can email Patient.Research@schlesingerassociates.com to see if they are a good fit for the interviews! Please see the attached flyer for complete information. Non Small Cell Lung Cancer _ Flyer.pdf
-
September 14 is the National Day of Action for Medical Research! The purpose of the Rally for Medical Research and the National Day of Action is to call on our nation's policymakers from all 50 states to make funding for National Institutes of Health (NIH) a national priority and raise awareness about the importance of continued investment in medical research that leads to MORE PROGRESS, MORE HOPE and MORE LIVES SAVED. Aside from supporting lifesaving research, NIH funding sustains a vibrant and innovative 21st century U.S. economy and supports jobs. Thanks to the $2 billion increase to the NIH budget that Congress approved for FY 2016, the U.S. saw an additional economic gain from investing in the NIH of $4 billion compared to 2015. In 2016, NIH funding and jobs generated by that funding produced $64.799 billion in new economic activity compared to $60.717 billion in 2015. Nineteen states saw an economic gain of $1 billion or more. Click here for more information and to register.
-
LUNGevity Foundation's Career Development Awards (CDA) for lung cancer research fund critical lung cancer research projects and offer the recipients world-class mentorship by LUNGevity’s prestigious Scientific Advisory Board. “LUNGevity created the CDAs to identify outstanding scientists early in their careers and encourage their continued development in the field of lung cancer research to grow a strong pipeline of dedicated lung cancer researchers,” says Charles Rudin, MD, PhD, Professor and Chief, Thoracic Oncology Service, at Memorial Sloan Kettering Cancer Center and chair of LUNGevity’s Scientific Advisory Board. “We work closely with these researchers with the hope of seeing them become the next generation of scientific superstars.” LUNGevity is proud to support the following researchers its 2017 Career Development Awards: Mehmet Altan, MD, The University of Texas MD Anderson Cancer Center, Identification of predictive markers of toxicity to immunotherapy. Dr. Altan will work to develop a way to predict which patients are most likely to develop serious side effects from some types of immunotherapy – these side effects can limit use of the treatments. Once patients can be flagged as high-risk for tissue damage, measures can be taken to limit the tissue damage proactively; patients may then experience better outcomes with their immunotherapy. Valsamo Anagnostou, MD, PhD, Johns Hopkins University, Dynamics of neoantigen landscape during immunotherapy in lung cancer. Dr. Anagnostou will leverage an existing clinical trial to discover why some patients become resistant to immunotherapy and to get a handle on how to help them overcome the resistance. Zofia Piotrowska, MD, Massachusetts General Hospital, Overcoming heterogeneity and resistance in EGFR-mutant NSCLC. Dr. Piotrowska intends to uncover the reason a subset of lung cancer patients develop resistance to their best option for treatment: a third-generation EGFR-blocking tyrosine kinase inhibitor drug. In addition, she will study a new combination of drugs in a clinical trial that may help patients who develop this type of drug resistance. “We have seen a lot of great progress in treating lung cancer, and we still need to better understand how lung cancer develops resistance to drugs, and why some patients experience side effects from treatment,” notes Upal Basu Roy, PhD, MPH, director of LUNGevity’s translational science research program. “Our funding this year’s group of awardees will help make progress in facing these challenges and continue to improve outcomes for lung cancer patients.” Each of these prestigious three-year awards is for $100,000 per year, renewable in the second and third years based on research progress. Awardees serve as non-voting members of LUNGevity’s distinguished Scientific Advisory Board for the terms of their awards. Awardees are mentored by senior lung cancer experts at their own institutions as well as by experts from the Scientific Advisory Board. Under the guidance of LUNGevity’s Scientific Advisory Board, a group of 21 prominent scientists and researchers, LUNGevity ensures that grants are awarded to the researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as extending and improving lives for lung cancer survivors. LUNGevity is the only lung cancer organization with a programmatic focus on early detection and a robust Career Development Award Program. Our researchers are working on finding a better way to detect lung cancer, and to better diagnose, treat, and prevent its recurrence. The foundation’s overall research program, including CDA awards, is a crucial factor in moving the science forward to improve outcomes for people living with lung cancer. LUNGevity’s Scientific Research Program is supported by the American Lung Association, Bristol-Myers Squibb, Genentech, The Thomas G. Labrecque Foundation, Upstage Lung Cancer, and individual donors. Read the full press release.
-
LUNGevity Foundation, the nation’s preeminent lung cancer research foundation, today announced that Alice T. Shaw, MD, PhD, has joined LUNGevity’s Scientific Advisory Board, a group of 20 world-renowned scientists and researchers that guides LUNGevity’s research program. The Scientific Advisory Board is integral to the Foundation, overseeing the scientific strategy and ensuring that grants are awarded to the researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as extending and improving lives of lung cancer survivors. LUNGevity is the only lung cancer organization with a programmatic focus on early detection and Career Development Awards. Our researchers are working on finding a better way to detect lung cancer, and to better diagnose, treat, and prevent its recurrence. The research program is a crucial factor in moving the science forward to improve outcomes for people living with lung cancer. Dr. Shaw is the Director of the Center for Thoracic Cancers and the Paula O’Keeffe Endowed Chair of Thoracic Oncology at Massachusetts General Hospital. She is also an Associate Professor of Medicine at Harvard Medical School. In addition to caring for patients with lung cancer, Dr. Shaw performs clinical and translational research. Her clinical research focuses on subsets of NSCLC that have unique driver mutations, such as EGFR, ALK, and ROS1. Her translational research focuses on understanding and making clear the mechanisms of resistance to targeted therapies; she is currently developing novel combination treatment strategies. Her research has helped to develop numerous FDA-approved targeted therapies for patients with oncogene-driven NSCLC, such as crizotinib (Xalkori®) for patients with ALK or ROS1 rearrangements. “We could not be happier that Dr. Shaw has joined our Scientific Advisory Board,” said Andrea Ferris, President and Chairman of LUNGevity Foundation. “She is a brilliant thinker, an innovator, and a compassionate advocate for her patients. In particular, her groundbreaking work that led to the development of Xalkori® has extended and improved the lives of many NSCLC patients. Her expertise and counsel will advance LUNGevity’s goal to increase and improve survivorship for those affected by lung cancer.” Read the full press release here.
-
LUNGevity Foundation has launched Patient FoRCe, the first-ever critical bridge to connect the voices of lung cancer patients — a significant population — with health care professionals, regulators, policymakers, and developers of drugs. “Lung cancer is the #1 cancer killer, taking the lives of 157,000 Americans every year. LUNGevity is leading the way in changing the paradigm of cancer treatment ─ from assuming patient wishes to evidence-based conclusions about what patients value,” said LUNGevity Chairman Andrea Stern Ferris. “Through Patient FoRCe, lung cancer patient voices will be heard and heeded as policy is developed, research is conducted, and treatment decisions are made.” Patient FoRCe, LUNGevity’s Patient-Focused Research Center, will undertake never-before studies of those living with lung cancer, collecting and sharing robust qualitative and quantitative data about lung cancer patients’ preferences and experiences to inform treatment, as well as relevant policy and research protocols. Patient FoRCe’s immediate focus will include continuing a study of patient preferences and experiences regarding access to care, treatment and diagnostic options, and the impact of symptoms on daily living, as well as conducting studies to facilitate patients’ access to biomarker testing, which is essential to implementing precision medicine. Patient FoRCe will also initiate a study into increasing adherence to lung cancer screening protocols for people at high risk for lung cancer. Additional projects will be based on stakeholder input and the guidance of an external advisory board of survivors, academic and community clinicians, industry partners, patient advocacy groups, and community partners. LUNGevity formally announced Patient FoRCe at the American Association for Cancer Research’s 2017 Annual Meeting in Washington, DC, on Sunday, April 2. Andrea Stern Ferris spoke to the urgency of the initiative, saying, “For too long, public policy, the practice of medicine, and drug development have not adequately integrated the viewpoint of patients. LUNGevity is determined to change that paradigm. By incorporating the patient’s voice into every step of the process – in policymaking, in trials, in treatments – we will improve outcomes for those diagnosed with lung cancer.” “Our goal is to uncover gaps in information, misperceptions about patient attitudes, and areas of unmet patient need,” explained Dr. Upal Basu Roy, Director of Patient FoRCe. “LUNGevity is the only organization driving this type of change for the lung cancer community, and we anticipate that our findings will shape the future of lung cancer care.” For more information about Patient FoRCe, visit www.LUNGevity.org/patientforce. Click here to read the full press release.
-
Thriving With Cancer A year ago, I was the healthiest 60-something year-old person I knew. Worked out every day; ate well; kept my weight down. My blood work-ups from my annual physicals were suitable for framing. Then, the bomb hit. In October 2016, I was diagnosed with Stage IV Lung Cancer. I had thoracic surgery, and due to the recovery from that plus the pain from the disease itself, I was on a hefty dose of opiate medications. For the rest of that year, I was pretty much a pain-ridden, groggy-headed vegetable. Lung Cancer Death Sentence? But, fortunately for me, that is not the end of my story, just the beginning. For anyone who knows about this disease, my diagnosis used to be a death sentence, and frankly still is for many, many people. I, however, had the good fortune to have tested positive for a genetic mutation that could be treated with an oral medication called Tarceva; more effective than chemo and with fewer and less severe side effects. I started on this medication on November 1, 2016. Before updating you on my status, let me digress just a bit. My Unwanted Intimacy with Lung Cancer It is my great un-fortune to have considerable history with lung cancer. I held my mother’s hand 8 years ago when she took her last breath after her bout with this disease. More recently, just 3 years ago, I held my little sister’s hand when she too succumbed to this miserable malady. And so, now it’s my turn. I am now 5 months into my treatment, and pretty much back into my normal life. At the same point in time for them, my mother was dead, and my sister was desperately trying a variety of chemotherapy cocktails, to no avail. So, what is different today? The Foundations for a New Approach to Treatment The difference today can be traced back to Richard Nixon (off all people), who declared a war on cancer way back in 1971 and funded significant research efforts to fight this war. I never thought I’d be thanking Nixon for anything, but he has my gratitude. The difference is also due to Craig Venter and Francis Collins, who sequenced the human genome in the early 2000s. And, the difference is due to thousands of researchers since then who’ve utilized the foundational research that resulted from these efforts and designed whole new approaches to treatment for cancer. When my mother was diagnosed 8 years ago, she had one option for treatment: chemo. When my sister was diagnosed 4 years ago, she had two options: chemo, or targeted therapy for a couple of gene mutation. When I was diagnosed, lung cancer treatment was already in the midst of a revolution. Chemotherapy, the go-to approach for all advanced lung cancer not that long ago, is the choice only half of the time today. The other half of lung cancer cases are being treated by either targeted treatment (like my own), or immunotherapy, both of which are far, far superior. So, I am the beneficiary of research. Pure and simple. The team of people who are caring for me at Lurie are fabulous, but it is the research that led to targeted treatments that is the key to my life. Where to Next? With a need and desire to do something with my gratitude, I spent time with Dr. Platanias, who heads up The Lurie Comprehensive Cancer Center, and he told me about OncoSET. This, my friends, is research that will lead to the next revolution in cancer treatment: PERSONALIZATION. If you haven’t already read the summary of this effort on this page, please do. Treatment of many diseases, cancer included, will become one-to-one. Each of us treated for exactly our unique profile. I believe it, but more importantly, so do those who truly know what they are talking about. I’m in the process of sending over a hefty donation of money to jump-start the lung cancer part of this program, and am participating in the research with my own data. I will update you on what I learn about myself through this process. Thriving with Cancer? Really?! When I started this note, I told you that a year ago, I was the healthiest person I knew. A year later, I am the healthiest person I know, who happens to have cancer. It’s not SURVIVING, it’s THRIVING. And, I have research to thank. I can think of no better place to invest your support, so please join me in giving to this worthy effort. Our children and their children with thank us, even if we’re not Nixon or Venter.
- 1 reply
-
- 5
-
-
- lung cancer
- research
- (and 2 more)
-
LUNGevity Announces Funding Opportunity for First-Ever Lung Cancer Early Detection and Interception Dream Team Call for ideas for SU2C-LUNGevity-American Lung Association collaboration FOR IMMEDIATE RELEASE Media Contact: Linda Wenger lwenger@lungevity.org (973) 449-3214 WASHINGTON, DC (February 6, 2017) – Building on the Foundation’s more than seven years of strategic investment in early detection research, LUNGevity Foundation, in collaboration with Stand Up To Cancer (SU2C) and the American Lung Association (through its LUNG FORCE initiative), is pleased to announce that the American Association for Cancer Research (AACR), SU2C’s scientific partner, has issued a Call for Ideas for research proposals that focus on lung cancer early detection and interception: catching precancerous cells and blocking them from turning into cancer cells. The interdisciplinary and multi-institutional SU2C-LUNGevity-American Lung Association Lung Cancer Interception Dream Team will be the first of its kind, with up to $7 million in funding support. As Dr. Pierre Massion, Professor of Medicine and Cancer Biology at Vanderbilt University, points out, "We understand the pathogenesis of lung cancer a lot better now. People have come to recognize that detecting the disease early and preventing it will require efforts between multiple disciplines to get there. The Lung Cancer Interception Dream Team is a huge step toward this goal." Dr. Massion is a member of LUNGevity’s distinguished Scientific Advisory Board and co-chairs the SU2C-LUNGevity-American Lung Association Joint Scientific Advisory Committee (JSAC). LUNGevity is the only lung cancer nonprofit with a programmatic focus on early detection, to find lung cancer when it is most treatable. Currently, only 15% of people with lung cancer are diagnosed in the earliest stages, resulting in a 5-year survival rate of only 17.7%. This project expands on LUNGevity’s investment in early detection research with the goal of developing an effective, widely available, noninvasive way of finding lung cancer early in all populations. Prioritized areas of interest for this project include research that accurately categorizes premalignant conditions according to risk of progression and that elucidates the underlying alterations that increase that risk; identification of new targets for developing therapeutic interventions of these early lesions; potential surrogate endpoints for clinical trials and regulatory approval; new tools for early detection and monitoring progression; the role of inflammation and immunosuppression in progression; or research targeted at generating sufficient knowledge to justify a clinical intervention to test novel hypotheses. Applicants for the grants are expected to show how their proposed projects will have positive benefit for patients in the near future, achieved through investigation by a multidisciplinary, multi-institutional, synergistic Dream Team of expert investigators. Priority will be given to applications that are characterized by a diversity of team members, including those from fields outside the traditional realms of biomedical research (e.g., physics, mathematics, engineering, health policy, and communications). Specific aims of the project may include basic research, translational studies, and population studies, but the overall proposal must have a strong clinical research component. Program details can be found at https://proposalcentral.altum.com. Letters of Intent are due by March 8, 2017. Read the full press release on LUNGevity's website.
-
Study Announcement: Lung Cancer Caregiver Study If you are over the age of 18 and a romantic partner and the caregiver of someone who has been diagnosed with lung cancer in the past two years, please consider contributing to this important study on the quality of life of caregivers of lung cancer patients and survivors. This study consists of completing a brief online survey at 2 different time points over the course of six months (initial time point and 6 months later). Some find the surveys helpful for reflecting on their caregiving experience, and you would be contributing to our understanding of the important but understudied topic of the challenges faced by caregivers. The survey questions will ask you about your feelings about caregiving, your quality of life, your physical health, and the physical health of the lung cancer survivor for whom you are a caregiver. The survey will take approximately 30 minutes at each of the two time points. This research is being conducted by Trisha Raque-Bogdan, Ph.D. of the University of Denver and Amanda Ginter, Ph.D., of Towson University. If you would like to participate in this research, please either go to https://udenver.qualtrics.com/SE/?SID=SV_etkPpCNDT9HwkKN or contact Trisha Raque-Bogdan at trisha.raque-bogdan@du.edu. Thank you for your consideration! Trisha Raque-Bogdan, Ph.D. Assistant Professor, Counseling Psychology University of Denver Amanda Ginter, Ph.D. Assistant Professor, Family Studies Towson University This study has been approved for posting by LUNGevity Foundation.
-
LUNGevity Foundation Issues Request for Applications for 2017 Career Development Awards for Translational Research in Lung Cancer Application now available online FOR IMMEDIATE RELEASE Media Contact: Austin Courtney acourtney@susandavis.com (202) 414-0791 Washington, D.C. (January 17, 2017) — LUNGevity has issued a Request for Applications (RFA) for translational research for Career Development Awards that will be granted in 2017. The RFA is available on the LUNGevity website at www.LUNGevity.org/career-development-awards and is also posted on the proposalCENTRAL website at https://proposalcentral.altum.com. LUNGevity’s Career Development Awards for Translational Research program was created to support future research leaders who will keep the field of lung cancer research vibrant with new ideas. Successful applicants may receive $100,000 per year for a possible period of three years and will participate as non-voting members of LUNGevity’s Scientific Advisory Board for the duration of the award. Applicants must be within the first five years of their faculty appointment. The Career Development Awards are mentored awards, and a mentoring plan is part of the required submission. Projects that will be funded in 2017 are expected to have a direct impact on the early detection of lung cancer or on the outcomes of lung cancer, or to provide a clear conceptual or experimental foundation for the future development of methods for early detection and/or individualized treatment, including through targeted therapy and immunotherapy. Letters of intent must be submitted by Friday, February 20, 2017. LUNGevity supports the largest research awards program of any lung cancer-focused organization in the United States. Since 2002, LUNGevity has funded 118 projects at 58 institutions in 23 states. About Lung Cancer in the U.S. About 1 in 15 Americans will be diagnosed with lung cancer in their lifetime More than 224,000 people in the U.S. will be diagnosed with lung cancer this year About 60%-65% of all new lung cancer diagnoses are among people who have never smoked or are former smokers Lung cancer takes more lives than the next four deadliest cancers (colorectal, pancreatic, breast, and prostate) combined Only 18% of all people diagnosed with lung cancer will survive 5 years or more, BUT if it’s caught before it spreads, the chance for 5-year survival improves dramatically About LUNGevity Foundation LUNGevity Foundation is firmly committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support, and education for all those affected by the disease. Our vision is a world where no one dies of lung cancer. For more information about LUNGevity Foundation, please visit www.LUNGevity.org. Click here to read the full press release online.
-
Edward Garon, MD, of UCLA joins the LUNGevity Foundation Scientific Advisory Board Dr. Garon brings expertise in clinical trials and other key areas to LUNGevity’s research program FOR IMMEDIATE RELEASE Media Contact: Austin Courtney acourtney@susandavis.com (202) 414-0791 WASHINGTON, DC (January 13, 2017) – LUNGevity Foundation, the nation’s preeminent lung cancer research foundation, today announced that Edward Garon, MD, has joined LUNGevity’s Scientific Advisory Board, a group of 19 world-renowned scientists and researchers who guide LUNGevity’s scientific strategy and research program. The Scientific Advisory Board is integral to the Foundation, overseeing the scientific approach and ensuring that grants are awarded to the researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as extending and improving lives for lung cancer survivors. LUNGevity is the only lung cancer organization with programmatic focuses on early detection and Career Development Awards. LUNGevity-funded researchers are working on finding a better way to detect lung cancer, and to better diagnose, treat, and prevent its recurrence. The research program is a crucial factor in moving the science forward to improve outcomes for people living with lung cancer. Dr. Garon is the Director of the Thoracic Oncology Program at the Jonsson Comprehensive Cancer Center at UCLA and Associate Professor of Medicine in the Division of Hematology-Oncology at David Geffen School of Medicine at UCLA. He has been the principal investigator of peer-reviewed grants from various funding organizations, including the National Cancer Institute. His focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II, and III clinical trials. Among these are trials that have led to the approval of drugs for the treatment of non-small cell lung cancer, including ramucirumab (Cyramza®) and the immunotherapy pembrolizumab (Keytruda®). “We are honored that Dr. Garon has joined our Scientific Advisory Board,” said Andrea Ferris, President and Chairman of LUNGevity Foundation. “His expertise and advice will be invaluable to furthering LUNGevity’s goal to improve outcomes for lung cancer patients.” Click here to read the complete press release on LUNGevity.org.
-
Good afternoon, LCSC members! Every Friday, I will start sharing a weekly clip report in this forum. I encourage you to reply to each thread to let us know what kind of news stories are most interesting/relevant to you. I'll post the first weekly clip report this Friday, December 16! With gratitude, Lauren -- Digital Community Manager LUNGevity Foundation
-
- 1
-
-
- lung cancer
- news
- (and 3 more)
-
The “Rally for Medical Research Hill Day” has nearly 200 people registered to participate in the meetings on Capitol Hill on Thursday, September 17. The states that are “not represented” at this point include: Alaska, Hawaii, Idaho, Indiana, Louisiana, Montana, Nebraska, New Hampshire, North Dakota, Oregon, South Dakota, Vermont, West Virginia, Wisconsin, and Wyoming. To register to participate please click the link below: http://rallyformedicalresearch.org/Pages/Hill-Day-Signup.aspx
